Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Kees

Showing results (181-190 of 376) with videos related to

Pageof 38
Sort By:
Cardiovascular Drugs and Therapy|May 4, 2017
Identification and Management of Statin-Associated Symptoms in Clinical Practice: Extension of a Clinician Survey to 12 Further CountriesRobert S Rosenson, Shravanthi R Gandra, Jan McKendrick, et al.
Journal of Clinical Lipidology|June 6, 2025
Global disparities in access to lipid-lowering therapies for patients with homozygous familial hypercholesterolemia - A physician surveyWillemijn A M Schonck, Janneke W C M Mulder, Tycho R Tromp, et al.
Journal of Clinical Lipidology|January 25, 2023
Adherence to statin treatment in patients with familial hypercholesterolemia: A dynamic prediction modelArjen J Cupido, Michel H Hof, Lotte M de Boer, et al.
Open Heart|September 20, 2024
Interleukin 6 plasma levels are associated with progression of coronary plaquesJordan M Kraaijenhof, Nick S Nurmohamed, Evangelos Tzolos, et al.
Cardiovascular Drugs and Therapy|February 9, 2019
Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial HypercholesterolemiaHenry N Ginsberg, Jaakko Tuomilehto, G Kees Hovingh, et al.
The Journal of Antimicrobial Chemotherapy|May 16, 2019
Plasma and tissue pharmacokinetics of fosfomycin in morbidly obese and non-obese surgical patients: a controlled clinical trialChristoph Dorn, David Petroff, Nancy Neumann, et al.
European Heart Journal|January 18, 2013
Identification of a loss-of-function inducible degrader of the low-density lipoprotein receptor variant in individuals with low circulating low-density lipoproteinVincenzo Sorrentino, Sigrid W Fouchier, Mohammad M Motazacker, et al.
The Lancet. Diabetes & Endocrinology|April 16, 2014
Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 studyBarbara Sjouke, Gisle Langslet, Richard Ceska, et al.
Lancet (London, England)|June 7, 2015
Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trialG Kees Hovingh, John J P Kastelein, Sander J H van Deventer, et al.
Clinical Therapeutics|January 27, 2009
Effects of short-term and long-term danazol treatment on lipoproteins, coagulation, and progression of atherosclerosis: two clinical trials in healthy volunteers and patients with hereditary angioedemaRakesh S Birjmohun, G Kees Hovingh, Erik S G Stroes, et al.
Pageof 38

Showing results (181-190 of 376) with videos related to

Sort By:
Pageof 38
Cardiovascular Drugs and Therapy|May 4, 2017
Identification and Management of Statin-Associated Symptoms in Clinical Practice: Extension of a Clinician Survey to 12 Further CountriesRobert S Rosenson, Shravanthi R Gandra, Jan McKendrick, et al.
Journal of Clinical Lipidology|June 6, 2025
Global disparities in access to lipid-lowering therapies for patients with homozygous familial hypercholesterolemia - A physician surveyWillemijn A M Schonck, Janneke W C M Mulder, Tycho R Tromp, et al.
Journal of Clinical Lipidology|January 25, 2023
Adherence to statin treatment in patients with familial hypercholesterolemia: A dynamic prediction modelArjen J Cupido, Michel H Hof, Lotte M de Boer, et al.
Open Heart|September 20, 2024
Interleukin 6 plasma levels are associated with progression of coronary plaquesJordan M Kraaijenhof, Nick S Nurmohamed, Evangelos Tzolos, et al.
Cardiovascular Drugs and Therapy|February 9, 2019
Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial HypercholesterolemiaHenry N Ginsberg, Jaakko Tuomilehto, G Kees Hovingh, et al.
The Journal of Antimicrobial Chemotherapy|May 16, 2019
Plasma and tissue pharmacokinetics of fosfomycin in morbidly obese and non-obese surgical patients: a controlled clinical trialChristoph Dorn, David Petroff, Nancy Neumann, et al.
European Heart Journal|January 18, 2013
Identification of a loss-of-function inducible degrader of the low-density lipoprotein receptor variant in individuals with low circulating low-density lipoproteinVincenzo Sorrentino, Sigrid W Fouchier, Mohammad M Motazacker, et al.
The Lancet. Diabetes & Endocrinology|April 16, 2014
Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 studyBarbara Sjouke, Gisle Langslet, Richard Ceska, et al.
Lancet (London, England)|June 7, 2015
Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trialG Kees Hovingh, John J P Kastelein, Sander J H van Deventer, et al.
Clinical Therapeutics|January 27, 2009
Effects of short-term and long-term danazol treatment on lipoproteins, coagulation, and progression of atherosclerosis: two clinical trials in healthy volunteers and patients with hereditary angioedemaRakesh S Birjmohun, G Kees Hovingh, Erik S G Stroes, et al.
Pageof 38